Male hypogonadism in diabetes
Abstract
Hypogonadism is defined as “inadequate gonadal function, as manifested by deficiencies in gametogenesis and/or the secretion of gonadal hormones”1. The gonads (ovaries or testes) produce hormones (testosterone, estradiol, antimullerian hormone, progesterone, inhibin B, activin) and gametes (eggs or sperm)
Downloads
References
Stedman’s Medical Dictionary. 26th ed. Baltimore: Williams & Wilkins, 1995: 836.
Yialamas MA, Hayes FJ. Androgens and the aging male and female. J Clin Endocrinol Metab. 2003;17:223–36. PubMed]
Guay A, Seftel AD, Traish A. Hypogonadism in men with erectile dysfunction may be related to a host of chronic illnesses. Int J Impot Res. 2010;22:9-19.
Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010
Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients–2002 update.Endocr Pract. 2002;8:440-456.
Tajar A, Forti G, O'Neill TW, et al.Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab.2010;95:1810-1818
International Diabetes Federation. Global burden. IDF Diabetes Atlas. 5th edition 2011
Danaei G, et al. Lancet. 2011;378(9785):31-40.
Shaw JE, et al. Diabetes Res Clin Pract. 2010;87:8-14
Mulligan T, Frick MF, Zuraw QC, StemhagenA, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762-769
Araujo AB, Esche GR, Kupelian V, et al.Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab.2007;92:4241-4247
Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920-5926
Hall SA, Araujo AB, Esche GR, et al.Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey. Arch Intern Med. 2008;168:1070-1076
Haffner SM et al. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 143: 889 – 897
Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with the development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. 2006;91:843-850.
Corona G, Mannucci E, Schulman C, et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol. 2006;50:595-604
Zumoff B, Strain GW, Miller LK, Rosner W, Senie R, Seres DS, Rosenfeld RS: Plasma free and non-sex-hormone binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endocrinol Metab 71:929 –931, 1990
Kapoor D, Malkin CJ, Channer KS, Jones TH: Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 63:239 –250, 2005
Oh JY, Barrett-Connor E, Wedick NM, Wingard DL: Endogenous sex hormones and the development of type 2 diabetes in older men and women. Diabetes Care 25: 55–60, 2002
Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB: Testosterone, sex hormone-binding globulin and the development of type 2 diabetes in iddle aged men. Diabetes Care 23:490–494, 2000
Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M, Nahoul K, Papoz L: Interrelation between plasma testosterone and plasma insulin in healthy adult men: the Telecom Study. Diabetologia 35:173–177, 1992
Dhindsa S, Prabhakar S, Sethi M, Bandyopadhyay A, Chaudhuri A, Dandona P: Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 89:5462–5468,2004
Like E, Gorenoi V, Wichers C, Muhlen A, Buren E, Brabant G: Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort, Clin Endocrinol (Oxf) 53:689–695, 2000
Marin P, Holman S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P: The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 16:991–997, 1992
Marin P, Krotkiewski M, Bjorntorp P: Androgen treatment of middle-aged, obese men: effects on metabolism, muscle, and adipose tissues. Eur J Med 1:329 –336, 1992
Kapoor D, Goodwin E, Channer KS, Jones TH: Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154:899–906, 2006
Boyanov MA, Boneva Z, Christov VG: Testosterone supplementation in men with type 2 diabetes, visceral obesity, and partial androgen deficiency. Aging Male,6:1–7, 2003
Kapoor D, Aldred H, Clark S, Channer KS, Jones TH 2007 Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 30:911–917
Grossmann M, Thomas MC, Panagiotopoulos S, Sharpe K, Macisaac RJ, Clarke S, Zajac JD, JerumsG 2008 Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 93:1834–1840
Rhoden EL, Ribeiro EP, Teloken C, Souto CA 2005 Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. BJU Int 96:867–870
Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM 2006 Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91:1995–2010
Pitteloud N, Dwyer AA, DeCruz S, Lee H, Boepple PA, Crowley Jr WF, Hayes FJ 2008 The relative role of gonadal sex steroids and gonadotropin-releasing hormone pulse frequency in the regulation of follicle-stimulating hormone secretion in men. J Clin Endocrinol Metab 93:2686– 2692
Watanobe H, Hayakawa Y 2003 Hypothalamic interleukin-1_ and tumor necrosis factor-_, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats. Endocrinology 144:4868–4875
Russell SH, Small CJ, Stanley SA, Franks S, Ghatei MA, Bloom SR 2001 The in vitro role of tumor necrosis factor-_ and interleukin-6 in the hypothalamicpituitary-gonadal axis. J Neuroendocrinol 13: 296–301
Morley JE, Charlton E, Patrick P, et al.Validation of a screening questionnaire for androgen deficiency in aging males.Metabolism. 2000;49:1239-1242.
Bhasin S, Cunningham GR, Hayes FJ, et al.Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006;91:1995-2010
Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients–2002 update.Endocr Pract. 2002;8:440-456.
Petak SM, Nankin HR, Spark RF, Swerdloff RS, Rodriguez-Rigau LJ. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients–2002 update. Endocr Pract. 2002;8:440-456
Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.J Clin Endocrinol Metab. 2007;92:405-413.
Nieschlag E, Behre HM, Bouchard P, et al.Testosterone replacement therapy: current trends and future directions. Hum ReprodUpdate. 2004;10:409-419.
Steidle CP. New advances in the treatment of hypogonadism in the aging male. Rev Urol. 2003;5 Suppl 1:S34-S40
Kapoor D, Goodwin E, Channer KS, JonesTH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899-906.
Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2) Study Diabetes care 2011:34:828-837
